BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dursun A, Poyraz A, Celik B, Akyol G. Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67. Pathol Oncol Res. 1999;5:104-106. [PMID: 10393360 DOI: 10.1053/paor.1999.0171] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M. Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol. 2006;12:2510-2516. [PMID: 16688795 DOI: 10.3748/wjg.v12.i16.2510] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
2 Zheng Y, Wang L, Zhang JP, Yang JY, Zhao ZM, Zhang XY. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma. World J Gastroenterol. 2010;16:339-344. [PMID: 20082479 DOI: 10.3748/wjg.v16.i3.339] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
3 Jiang YA, Zhang YY, Luo HS, Xing SF. Mast cell density and the context of clinicopathological parameters and expression of p185, estrogen receptor, and proliferating cell nuclear antigen in gastric carcinoma. World J Gastroenterol. 2002;8:1005-1008. [PMID: 12439914 DOI: 10.3748/wjg.v8.i6.1005] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
4 Seo KW, Jeon T, Kim S, Kim SS, Kim K, Suh BJ, Hwang S, Choi S, Ryu S, Min JS, Lee YJ, Jee YS, Chae H, Yang DH, Lee SH. Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer. J Gastric Cancer 2017;17:52-62. [PMID: 28337363 DOI: 10.5230/jgc.2017.17.e6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Bayrak M, Olmez OF, Kurt E, Cubukcu E, Evrensel T, Kanat O, Manavoglu O. Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer. Clin Transl Oncol. 2013;15:307-312. [PMID: 22911549 DOI: 10.1007/s12094-012-0921-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
6 Pinto-de-Sousa J, David L, Almeida R, Leitão D, Preto JR, Seixas M, Pimenta A. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol. 2002;10:247-256. [PMID: 12490974 DOI: 10.1177/106689690201000402] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.2] [Reference Citation Analysis]
7 Bizari L, Borim AA, Leite KR, Gonçalves Fde T, Cury PM, Tajara EH, Silva AE. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet. 2006;165:41-50. [PMID: 16490596 DOI: 10.1016/j.cancergencyto.2005.08.031] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
8 Sereno M, De Castro J, Cejas P, García-Cabezas MA, Belda C, Casado E, Feliu J, Gómez C, López M, Barón MG. Expression profile as predictor of relapse after adjuvant treatment in gastric cancer. J Gastrointest Cancer. 2012;43:181-189. [PMID: 21360269 DOI: 10.1007/s12029-011-9267-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. [DOI: 10.1111/j.1365-2559.2008.03028.x] [Cited by in Crossref: 719] [Cited by in F6Publishing: 621] [Article Influence: 55.3] [Reference Citation Analysis]
10 Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, Romagnoli S, Bosari S. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol 2013;26:816-24. [DOI: 10.1038/modpathol.2012.228] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
11 Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, Li HQ, Zhang SB, Sun Z. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol 2017;15:68. [PMID: 28327158 DOI: 10.1186/s12957-017-1132-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
12 Satiroglu-Tufan NL, Bir F, Calli-Demirkan N. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. World J Gastroenterol 2006;12:3283-7. [PMID: 16718853 DOI: 10.3748/wjg.v12.i20.3283] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]